Antitumor and Antiangiogenic Properties of Gold(III) Complexes Containing Cycloaurated Triphenylphosphine Sulfide Ligands.

A family of stable anticancer gold(III)-based therapeutic complexes containing cyclometalated triphenylphosphine sulfide ligands have been prepared. The anticancer properties of the newly developed complexes [AuCl{κ-2-CHP(S)Ph}] (), [Au(κ-SCNEt){κ-2-CHP(S)Ph}]PF (), [AuCl(dppe){κ-2-CHP(S)Ph}]Cl (), and [Au(dppe){κ-2-CHP(S)Ph}][PF] () were investigated toward five human cancer cell lines [cervical (HeLa), lung (A549), prostate (PC3), fibrosarcoma (HT1080), and breast (MDA-MB-231)]. cytotoxicity studies revealed that compounds - displayed potent cell growth inhibition (IC values in the range of 0.17-2.50 μM), comparable to, or better than, clinically used cisplatin (0.63-6.35 μM). Preliminary mechanistic studies using HeLa cells indicate that the cytotoxic effects of the compounds involve apoptosis induction through ROS accumulation. Compound also demonstrated significant inhibition of endothelial cell migration and tube formation in the angiogenesis process. Evaluation of the antitumor activity of compound in nude mice bearing cervical cancer cell (HeLa) xenografts indicated significant tumor growth inhibition (55%) with 1 mg/kg dose (every 3 days) compared with the same dose of cisplatin (28%). These results demonstrate the potential of gold(III) complexes containing cyclometalated triphenylphosphine sulfide ligands as novel metal-based anticancer agents.